International Clinical Trial: Anlotinib plus bemipalimab versus toripalimab plus chemotherapy as first-line therapy in patients with advanced esophageal squamous cell carcinoma harboring specific gene mutations: a randomized, open-label, parallel-group, multicenter, phase III trial

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129030) titled 'Anlotinib plus bemipalimab versus toripalimab plus chemotherapy as first-line therapy in patients with advanced esophageal squamous cell carcinoma harboring specific gene mutations: a randomized, open-label, parallel-group, multicenter, phase III trial' on July 29.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital of Zhengzhou University

Condition: Esophageal cancer

Intervention: Control group:Toripalimab plus chemotherapy

Recruitment Status: Recruiting

Phase: 3

Date of First Enrollment: 2026-03-23

Target Sample Size: Control group:289;Experimental...